4
Changes in Ownership
Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-23-016053
EVP and Chief Medical Officer sold 3,881 shares at $45.25 ($175,615)
- EVP and Chief Medical Officer acquired 2,663 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bedrosian Camille L EVP and Chief Medical Officer | 2023-03-01 | Grant or award | +2,663 | 50,601 | D: show line 1 in the form | ||
| Bedrosian Camille L EVP and Chief Medical Officer | 2023-03-01 | Sale | −3,881 | $45.25 | $175,615 | 46,720 | D: show line 2 in the form |
| Open-market sales · 3,881 sh · avg $45.25 · $175,615 | |||||||
Loading xslF345X03/doc4.xml…